Insights

The specialty pharmaceutical market is undergoing a structural realignment as high-value biologics and small molecules face their first wave of […]

The Patent Strategy That Keeps Failing Biologic drug developers have spent decades trying to own entire therapeutic concepts. Claim the

Why Five Years Is the Only Number That Matters in Pharma When Pfizer’s patent on Lipitor expired in November 2011,

The Problem With Betting Everything on One Patent Every pharmaceutical brand team eventually confronts the same uncomfortable math. The active

The global biopharmaceutical industry is approaching a critical juncture as it faces a massive wave of patent expirations for some

The Efficiency Trap: Why Lean Supply Chains Broke in 2024 The global pharmaceutical landscape is currently navigating a period of

Why Most Cost-Cutting Advice Fails Employers and Plan Sponsors Every benefits consultant in America will tell you the same thing:

Pfizer killed torcetrapib in 2006 after spending $800 million on a cholesterol drug that raised blood pressure instead of lowering

The generic drug industry, often relegated to the background of high-profile blockbuster headlines and breakthrough therapy announcements, is not merely